Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1537-1544

  Kume, Manabu ^a   Yasui, Hiroyuki ^b   Yoshikawa, Yutaka ^b   Horinouchi, Masanori ^c   Higashiguchi, Kanae ^a   Kobayashi, Yoko ^a   Kuroda, Daisuke ^d   Hirano, Takeshi ^a   Hirai, Midori ^a   Nakamura, Tsutomu ^c  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c HIMEJI DOKKYO UNIVERSITY   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Cystatin C; Esophageal cancer; Platinum; Renal function

Indexed keywords

CISPLATIN; CREATININE; CYSTATIN C; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; JAPANESE; MALE; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE PERIOD; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CREATININE; CYSTATIN C; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84863795706     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1860-8     Document Type: Article

References (27)

1. Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65(2):307-314
2. Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21(1):33-64
3. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A (2005) Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 38(1):1-8
4. Newman DJ (2002) Cystatin C. Ann Clin Biochem 39(Pt 2):89-104
5. Chew JS, Saleem M, Florkowski CM, George PM (2008) Cystatin C-a paradigm of evidence based laboratory medicine. Clin Biochem Rev 29(2):47-62
6. Schmitt A, GladieV L, Lansiaux A, Bobin-Dubigeon C, Etienne- Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E (2009) A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 15(10):3633-3639
7. Tanaka A, Aiba T, Otsuka T, Suemaru K, Nishimiya T, Inoue T, Murase M, Kurosaki Y, Araki H (2010) Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother 54(2):778-782
8. Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39(1-2):131-137
9. Benohr P, Grenz A, Hartmann JT, Muller GA, Blaschke S (2006) Cystatin C-a marker for assessment of the glomerular Wltration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res 29(1):32-35
10. Bárdi E, Bobok I, Oláh AV, Oláh E, Kappelmayer J, Kiss C (2004) Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatr Nephrol 19(10):1145-1147
11. Ktabuc B, Vrhovec L, Ktabuc-Kilih M, Cizej TE (2000) Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 46(2):193-197
12. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-Xuorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68-74
13. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H (2003) Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study- JCOG9204. J Clin Oncol 21(24):4592-4596
14. Adhim Z, Lin X, Huang W, Morishita N, Nakamura T, Yasui H, Otsuki N, Shigemura K, Fujisawa M, Nibu K, Shirakawa T (2012) E10A, an adenovirus carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous cell carcinoma. Cancer Gene Ther 19:144-152
15. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4(11):879-885
16. Hoek FJ, Kemperman FA, Krediet RT (2003) A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular Wltration rate. Nephrol Dial Transplant 18(10):2024-2031
17. Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW (1998) Biological variation of cystatin C: implications for the assessment of glomerular Wltration rate. Clin Chem 44(7):1535-1539
18. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932-2947
19. Bjarnadottir M, Grubb A, Olafsson I (1995) Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest 55(7):617-623
20. Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N (2011) Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol 68(3):653-659
21. Nakade S, Ohno T, Kitagawa J, Hashimoto Y, Katayama M, Awata H, Kodama Y, Miyata Y (2008) Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy- induced nausea and vomiting. Cancer Chemother Pharmacol 63(1):75-83
22. Fehrenbacher N, Bastholm L, Kirkegaard-Sorensen T, Rafn B, Bottzauw T, Nielsen C, Weber E, Shirasawa S, Kallunki T, Jaattela M (2008) Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res 68(16):6623-6633
23. Seo HR, Bae S, Lee YS (2009) Radiation-induced cathepsin S is involved in radioresistance. Int J Cancer 124(8):1794-1801
24. Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M, Kruyt FA (2010) Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-Xuorouracil in colon cancer cells. Int J Cancer 126(10): 2457-2468
25. Miki I, Tamura T, Nakamura T, Makimoto H, Hamana N, Uchiyama H, Shirasaka D, Morita Y, Yamada H, Aoyama N, Sakaeda T, Okumura K, Kasuga M (2005) Circadian variability of pharmacokinetics of 5-Xuorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit 27(3):369-374
26. Martino S, Tiribuzi R, Ciraci E, Makrypidi G, D'Angelo F, di Girolamo I, Gritti A, de Angelis GM, Papaccio G, Sampaolesi M, Berardi AC, Datti A, Orlacchio A (2011) Coordinated involvement of cathepsins S, D and cystatin C in the commitment of hematopoietic stem cells to dendritic cells. Int J Biochem Cell Biol 43(5):775-783
27. Grzonka Z, Jankowska E, Kasprzykowski F, Kasprzykowska R, Lankiewicz L, Wiczk W, Wieczerzak E, Ciarkowski J, Drabik P, Janowski R, Kozak M, Jaskolski M, Grubb A (2001) Structural studies of cysteine proteases and their inhibitors. Acta Biochim Pol 48(1):1-20